Metraipolis › archive › dc_0406856591a9
"A sense of the bigger picture:" A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use — Europe PMC PMID:36516137
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/36516137
- DOI
- 10.1371/journal.pone.0279073
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-10T01:00:19.185Z
- SHA-256 of the archived text
6c5e5951a2f919422f9846a0c89b9b7fb04886f6e9ba346a7bb25249d8452ef6- Stable URL of this page
https://metraipolis.com/documento/dc_0406856591a9
How to cite
"A sense of the bigger picture:" A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use — Europe PMC PMID:36516137 — Europe PMC (en), https://europepmc.org/article/MED/36516137 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_0406856591a9 (Metraipolis archive dc_0406856591a9, sha256 6c5e5951a2f919422f9846a0c89b9b7fb04886f6e9ba346a7bb25249d8452ef6)
BibTeX
@misc{dc0406856591a9,
title = {"A sense of the bigger picture:" A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use — Europe PMC PMID:36516137},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/36516137},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_0406856591a9; sha256 6c5e5951a2f919422f9846a0c89b9b7fb04886f6e9ba346a7bb25249d8452ef6},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/36516137. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Objectives: People with bipolar disorder (BD) spend more time depressed than manic/hypomanic, and depression is associated with greater impairments in psychosocial functioning and quality of life than mania/hypomania. Emerging evidence suggests psilocybin, the psychoactive compound in "magic mushrooms," is a promising treatment for unipolar depression. Clinical trials of psilocybin therapy have excluded people with BD as a precaution against possible adverse effects (e.g., mania). Our study centered the experiences of adults living with BD who consumed psilocybin-containing mushrooms, and aimed to (1) understand its subjective impacts on BD symptoms, (2) deepen understanding of Phase I survey results, and (3) elucidate specific contextual factors associated with adverse reactions in naturalistic settings. Methods: Following an international survey (Phase I), follow-up interviews were conducted with 15 respondents (Phase II) to further understand psilocybin use among adults with BD. As part of a larger mixed-methods explanatory sequential design study, reflexive thematic analysis was used to elaborate findings. Results: Three major themes containing sub-themes were developed. (1) Mental Health Improvements: (1.1) decreased impact and severity of depression, (1.2) increased emotion processing, (1.3) development of new perspectives, and (1.4) greater relaxation and sleep. (2) Undesired Mental Health Impacts: (2.1) changes in sleep, (2.2) increased mania severity, (2.3) hospitalization, and (2.4) distressing sensory experiences. (3) Salient Contextual Factors for psilocybin use included: (3.1) poly-substance use and psilocybin dose, (3.2) solo versus social experiences, and (3.3) pre-psilocybin sleep deprivation. Conclusion: Our findings demonstrate both benefits and risks of psilocybin use in this population. Carefully designed clinical trials focused on safety and preliminary efficacy are warranted. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2022 (prima pubblicazione 2022-12-14). Identificativi: PMID 36516137 · PMCID PMC9749989 · DOI 10.1371/journal.pone.0279073. Descrittori MeSH principali: Bipolar Disorder. Pagina: https://europepmc.org/article/MED/36516137 — https://doi.org/10.1371/journal.pone.0279073. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-09T23:57:58.315Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.